Adding Winrevair to standard pulmonary arterial hypertension (PAH) treatment is generally safe and effective, a pooled trial ...

Right heart failure occurs when the heart is too weak to pump adequate blood supply to the lungs. Prostacyclin analogs were the first class of drugs approved for treating PAH. They work by mimicking ...

Future Cardiol. 2013;9(3):335-349. Research into prostacyclin analogs for the treatment of WHO Group 2 PH has been limited, likely due to the early termination of the FIRST trial. [55] This study ...

Q4 2024 Earnings Call Transcript February 26, 2025 United Therapeutics Corporation beats earnings expectations. Reported EPS ...

Reports Q4 revenue $735.9M, consensus $734.74M. “I want to congratulate every Unitherian for their relentless dedication, which has allowed us ...

MannKind’s future hinges on Tyvaso DPI's growth, R&D prospects, and financial stability despite competition and risks.

United Therapeutics Corp (UTHR) reports a third consecutive year of record revenue, strategic clinical advancements, and significant shareholder returns.

4 University of Giessen and Marburg Lung Center (UGMLC), member of the German Center of Lung Research (DZL), Giessen, Germany Until recently, three classes of medical therapy were available for the ...

Compared with the 2009 recommendations, the 2016 recommendations include phosphodiesterase type 5 (PDE-5) inhibitors for the treatment of SSc-related RP and DUs, riociguat, new aspects for endothelin ...

Good morning and welcome to the United Therapeutics Corporation, fourth quarter 2024 corporate update. My name is Cindy, and I will be your conference operator today. (Operator Instructions) Please ...

prostacyclin and endothelium-derived hyperpolarizing factors. In the case of AIS, DM199 is intended to enhance blood flow and boost neuronal survival in the ischemic penumbra by dilating ...